A Clinical Trial of a Monocomponent Pertussis Toxoid Vaccine

Hedenskog, Staffan; Granström, Marta; Olin, Patrick; Tiru, Mandayam; Sato, Yuji

doi:10.1001/archpedi.1987.04460080030021

Cited by 13 publications

(7 citation statements)

References 9 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Children who had received the two-component acellular vaccine for primary immunization showed a significantly higher PT-IgE response to the booster dose than the children who had received the mono-component vaccine. This was the only noted difference with regard to the vaccines given in primary immunization and may seem unexpected as the mono-component vaccine had a higher pertussis toxoid content and also induced a higher IgG antibody response (16). The lack of correlation between IgG and IgE responses, as noted in the present and a previous study by us (19, could indicate the possibility to manufacture vaccines inducing good IgG respones without simultaneously eliciting IgE antibodies.…”

Section: Discussionsupporting

confidence: 47%

Immunogloblin E and G responses to pertussis toxin after booster immunization in relation to atopy, local reactions and aluminium content of the vaccines

Odelram

Granström²,

Hedenskog

et al. 1994

Pediatric Allergy Immunology

View full text Add to dashboard Cite

The role of aluminium for IgG and IgE responses to pertussis toxin (PT), as well as for side effects, was investigated in 49 children with known atopy status. Primary immunization had been given with an adsorbed monocomponent or an adsorbed two-component acellular pertussis vaccine. The children were then randomized to receive a booster immunization with either aluminium-adsorbed or non-adsorbed, whole cell, pertussis vaccine. Both vaccines induced good IgG responses with the adsorbed vaccine giving higher post-booster levels (p < 0.05). The adsorbed vaccine was, however, associated with more local side effects (p < 0.05) and tended to induce higher PT-IgE responses than the non-adsorbed vaccine. Furthermore, individuals who had received the two-component vaccine as primary immunization had higher PT-IgE responses after the booster, compared with individuals initially receiving the monocomponent vaccine (p = 0.041). No correlation between PT-IgE and PT-IgG levels was seen in any of the groups. Total serum IgE levels correlated to PT IgE levels, particularly in children with atopy (r = 0.950, p < 0.001). The addition of aluminium to the pertussis vaccine, was, thus, associated with a stronger IgG antibody response, but tended also to induce a stronger IgE antibody response. The correlation between total IgE and PT-IgE, which was most prominent in children with atopy, indicates that the role of immunization for the development of allergy merits further studies.

show abstract

Section: Discussionsupporting

confidence: 47%

Immunogloblin E and G responses to pertussis toxin after booster immunization in relation to atopy, local reactions and aluminium content of the vaccines

Odelram

Granström²,

Hedenskog

et al. 1994

Pediatric Allergy Immunology

View full text Add to dashboard Cite

show abstract

“…The two-component (FHA+PT) and mono-component (PT) vaccine were evaluated for adverse reactions and immunogenicity in two separate phase 2 studies in previously non-immunized infants (6,7). Such studies do not usuatty yield data concerning protective effect.…”

Section: Protective Effect Of Acellular Pertussis Vaccinesmentioning

confidence: 99%

Protective effect of acellular pertussis vaccines

Blennow

Hedenskog

Granström³

1988

Eur. J. Clin. Microbiol. Infect. Dis.

View full text Add to dashboard Cite

Two acellular pertussis vaccines, a mono-component toxoid of pertussis toxin and a two-component vaccine containing both the toxoid and filamentous haemagglutinin, were used for primary immunization of infants 5 1/2 to 10 months of age in two clinical trials in Sweden. Over a follow-up period of 12 to 17 months, 37 children were exposed to pertussis in the household or a daycare centre. Only one child developed mild, culture-confirmed pertussis as opposed to the expected number of 30 to 33 cases based on an assumed attack rate of 80-90% in non-immunized children. These preliminary findings indicate that, given as primary immunization to infants, the vaccines provide protection against pertussis.

show abstract

“…Pertussis toxin (PT) is an oligomeric protein released into the culture medium by Bordetella pertussis, the human pathogen responsible for whooping cough (18,21). This protein, which is a major virulence factor and the main component of new acellular vaccines against whooping cough (2,14,16,17,19,22), contains five noncovalently linked subunits (Si, S2, S3, S4, and S5) which are assembled into the A monomer (subunit S1) and the B oligomer (containing subunits S2, S3, S4, and S5, present in a 1:1:2:1 ratio) (18,21). Each of the five subunits is synthesized as a precursor containing a secretory leader peptide and is secreted into the periplasm of B. pertussis, where toxin assembly takes place.…”

mentioning

confidence: 99%